secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0000950170-24-053248
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint's DURAVYU misses Phase 2 NPDR primary endpoint; shows reduced progression at 9 months
--------------------------------------------------------------------------------

- Primary endpoint not met: 5% (3mg), 0% (2mg) vs 5% control achieved ≥2-step DRSS improvement at 9 months.
- 86% (3mg) and 80% (2mg) patients stable/improved vs 70% control; 0% (3mg) worsened ≥2-step vs 10% control.
- No drug-related serious adverse events reported; favorable safety profile maintained.
- Company on track for Phase 3 wet AMD trial (LUGANO) in H2 2024 and DME trial (VERONA) data in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024053248/0000950170-24-053248-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024053248/eypt-20240506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053248

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer